Document

Chris Simon, Haemonetics’ CEO, stated: “We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long-term growth and shareholder value.”

Gross margin was 59.8% in the first quarter of fiscal 2027, which was relatively flat when compared with 59.8% in the first quarter of fiscal 2026. Operating expenses were $145.3 million, up $7.0 million, or 5.0%, compared with the first quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $57.5 million and a 16.9% operating margin in the first quarter of fiscal 2027, compared with operating income of $53.9 million and a 16.8% operating margin in the first quarter of fiscal 2026. The effective income tax rate was 30.6% in the first quarter of fiscal 2027, compared with 24.7% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls and valuation allowance impacts related to losses in certain recently acquired jurisdictions. First quarter fiscal 2027 net income and earnings per diluted share were $33.0 million and $0.72, respectively, compared with $34.0 million and $0.70, respectively, in the first quarter of fiscal 2026.

Adjusted operating expenses were $125.6 million, up $7.9 million, or 6.7%, compared with the first quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the first quarter of fiscal 2027 was $79.3 million, down $1.7 million, or 2.2%, compared with the first quarter of fiscal 2026. Adjusted operating margin was 23.4%, down 70 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the first quarter of fiscal 2027 was 25.7%, up 180 basis points when compared with 24.9% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls.

First quarter fiscal 2027 cash flow from operating activities was $52.3 million, up $34.9 million, and free cash flow was $39.1 million, up $36.6 million, each when compared with the same period of fiscal 2026. The primary driver of increased operating cash flow as compared to the same period of fiscal 2026 was favorable working capital adjustments driven by the timing of collections on receivables. Free cash flow benefitted from lower non-cash transfers from Haemonetics equipment, partially offset by higher capital expenditures.

The Company will host a conference call with investors and analysts to discuss first quarter fiscal 2027 results on Thursday, August 6, 2026 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register-conf.media-server.com/register/BI10b970fcb46348a6ab6968b8585a2627. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above.

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company’s products; the Company’s ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company’s ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company’s ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.

This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

When used in this release, organic revenue growth excludes the impact of currency fluctuation and the exit of certain liquid solution products. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest and other income/expense, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition, integration and divestiture related costs, certain tax settlements, unusual or infrequent and material litigation-related charges, equity method losses, and remeasurement of contingent consideration. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.

A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow conversion guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs, impairment charges and capital expenditures, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.


Haemonetics Corporation Financial Summary
Condensed Consolidated Statements of Income (Unaudited)

	Three Months Ended
			6/27/2026			6/28/2025			Inc/(Dec) %

		(Dollars and Shares in Thousands, Except Per Share Data)
Net revenues			$	339,380		$	321,394		5.6%
Cost of goods sold			136,577			129,150			5.8%
Gross profit			202,803			192,244			5.5%

Research and development			16,200			16,261			(0.4)%
Selling, general and administrative			118,941			110,719			7.4%
Amortization of acquired intangible assets			10,204			11,392			(10.4)%



Total Operating expenses			145,345			138,372			5.0%

Operating income			57,458			53,872			6.7%

Interest and other expense, net			(9,884)			(8,703)			13.6%

Income before provision for income taxes			47,574			45,169			5.3%

Provision for income taxes			14,564			11,138			30.8%

Net income			$	33,010		$	34,031		(3.0)%


Net income per common share assuming dilution			$	0.72		$	0.70		2.9%

Weighted average shares outstanding
Basic			45,361			48,111
Diluted			45,704			48,353

Profit Margins:									Inc/(Dec) %
Gross profit			59.8		%	59.8		%	—%
Research and development			4.8		%	5.1		%	(0.3)%
Selling, general and administrative			35.0		%	34.4		%	0.6%
Operating income			16.9		%	16.8		%	0.1%
Income before provision for income taxes			14.0		%	14.1		%	(0.1)%
Net income			9.7		%	10.6		%	(0.9)%


Revenue Analysis by Business Unit (Unaudited)



















	Three Months Ended
	6/27/2026		6/28/2025		Reported growth		Currency impact		Strategic Exits(1)		Organic growth(2)

	(Dollars in Thousands)
Revenues by business unit


Plasma	$	155,524	$	145,074	7.2	%	0.1	%	(1.1)	%	8.2	%
Other(3)	35,794		36,662		(2.4)	%	0.4	%	—	%	(2.8)	%
Apheresis	$	191,318	$	181,736	5.3	%	0.2	%	(0.9)	%	6.0	%

Interventional Technologies(4)	$	59,942	$	58,483	2.5	%	(0.3)	%	—	%	2.8	%
Blood Management Technologies(5)	88,120		81,175		8.6	%	0.5	%	—	%	8.1	%
MedSurg	$	148,062	$	139,658	6.0	%	0.1	%	—	%	5.9	%

Total net revenues	$	339,380	$	321,394	5.6	%	0.2	%	(0.5)	%	5.9	%


Condensed Consolidated Balance Sheets (Unaudited)

	June 27, 2026		March 28, 2026

	(Dollars in Thousands)
Assets
Cash and cash equivalents	$	223,384	$	245,440
Accounts receivable, net	216,071		216,855
Inventories, net	306,739		306,370
Other current assets	64,638		66,214
Total current assets	810,832		834,879
Property, plant & equipment, net	303,778		305,761
Intangible assets, net	434,512		447,655
Goodwill	656,884		656,368
Other assets	159,394		151,262
Total assets	$	2,365,400	$	2,395,925

Liabilities & Stockholders' Equity
Short-term debt & current maturities	$	4,956	$	5,015
Other current liabilities	258,279		277,584
Total current liabilities	263,235		282,599
Long-term debt	1,169,202		1,219,565
Other long-term liabilities	95,862		97,441
Stockholders' equity	837,101		796,320
Total liabilities & stockholders' equity	$	2,365,400	$	2,395,925


Condensed Consolidated Statements of Cash Flows (Unaudited)

	Three Months Ended
	June 27, 2026		June 28, 2025

	(Dollars in Thousands)
Cash Flows from Operating Activities:
Net income	$	33,010	$	34,031
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	27,111		28,758

Amortization of fair value inventory step-up	—		2,436
Share-based compensation expense	9,311		9,312




Deferred income taxes	668		(3,231)
Change in other non-cash operating activities	2,227		1,571
Change in operating assets and liabilities:
Change in accounts receivable, net	297		3,557
Change in inventories, net	(1,004)		3,296
Change in prepaid income taxes	6,101		3,346
Change in other assets and other liabilities	(12,783)		(17,785)
Change in accounts payable and accrued expenses	(12,615)		(47,896)
Net cash provided by operating activities	52,323		17,395
Cash Flows from Investing Activities:
Capital expenditures	(7,906)		(3,754)
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	(5,565)		(11,460)
Proceeds from sale of property, plant and equipment	237		297


Other investments	(9,000)		(18,083)
Net cash used in investing activities	(22,234)		(33,000)
Cash Flows from Financing Activities:
Repayments, net of borrowings	(51,563)		(1,563)




Proceeds from employee stock programs	3,549		3,938
Cash used to net share settle employee equity awards	(3,500)		(4,781)
Other financing activities	(14)		(36)
Net cash used in financing activities	(51,528)		(2,442)
Effect of exchange rates on cash and cash equivalents	(617)		4,182
Net Change in Cash and Cash Equivalents	(22,056)		(13,865)
Cash and Cash Equivalents at Beginning of the Period	245,440		306,763
Cash and Cash Equivalents at End of Period	$	223,384	$	292,898

Free Cash Flow Reconciliation:
Cash provided by operating activities	$	52,323	$	17,395
Capital expenditures	(7,906)		(3,754)
Additions to Haemonetics equipment	(5,565)		(11,460)
Proceeds from sale of property, plant and equipment	237		297
Free cash flow	$	39,089	$	2,478


Reconciliation of Adjusted Measures for First Quarter of FY27 and FY26 (Unaudited)

	Gross profit			Operating expenses			Operating income (loss)			Interest and other expense		Provision (benefit) for income taxes		Net income (loss)			Earnings per diluted share

Three Months Ended June 27, 2026:	(Dollars in Thousands, Except Per Share Data)
Reported	$	202,803		$	145,345		$	57,458		$	(9,884)	$	14,564	$	33,010		$	0.72
Amortization of acquired intangible assets	—			(10,204)			10,204			—		2,285		7,919			0.16

Integration and transaction costs	1,285			(1,434)			2,719			—		(423)		3,142			0.07
Restructuring costs	783			(1,515)			2,298			—		537		1,761			0.04
Restructuring related costs	10			50			(40)			—		—		(40)			—
Digital transformation costs	—			(6,163)			6,163			—		1,563		4,600			0.10


Litigation-related charges	—			(457)			457			—		—		457			0.01




Equity method losses	—			—			—			1,000		255		745			0.02
Discrete tax items	—			—			—			—		(696)		696			0.02
Adjusted	$	204,881		$	125,622		$	79,259		$	(8,884)	$	18,085	$	52,290		$	1.14
Adjusted, as a percentage of net revenues	60.4		%	37.0		%	23.4		%					15.4		%

	Gross profit			Operating expenses			Operating income (loss)			Interest and other (expense) income		Provision (benefit) for income taxes		Net income (loss)			Earnings per diluted share

Three Months Ended June 28, 2025:	(Dollars in Thousands, Except Per Share Data)
Reported	$	192,244		$	138,372		$	53,872		$	(8,703)	$	11,138	$	34,031		$	0.70
Amortization of acquired intangible assets	—			(11,392)			11,392			—		2,923		8,469			0.18
Amortization of fair value inventory step-up	2,436			—			2,436			—		618		1,818			0.04
Integration and transaction costs	1,030			(1,652)			2,682			2,022		1,212		3,492			0.07
Restructuring costs	(385)			(1,651)			1,266			—		290		976			0.02
Restructuring related costs	(13)			(71)			58			—		9		49			—
Digital transformation costs	—			(5,355)			5,355			—		1,334		4,021			0.08


Litigation-related charges	—			(584)			584			—		148		436			0.01


Remeasurement of contingent consideration	—			93			(93)			—		(34)		(59)			—


Adjusted	$	195,312		$	117,760		$	77,552		$	(6,681)	$	17,638	$	53,233		$	1.10
Adjusted, as a percentage of net revenues	60.8		%	36.6		%	24.1		%					16.6		%


			Exhibit 99.1

Investor Contacts			Media Contact
Olga Guyette, Vice President-Investor Relations & Treasury			Josh Gitelson, Sr. Director-Global Communications
(781) 356-9763			(781) 356-9776
olga.guyette@haemonetics.com			josh.gitelson@haemonetics.com

David Trenk, Sr. Manager-Investor Relations
(203) 733-4987
david.trenk@haemonetics.com


	First Quarter Fiscal 2027 Reported
	(Dollars in Millions)
Apheresis	$191.3	5.3%
MedSurg	$148.1	6.0%
Total net revenue	$339.4	5.6%


	Total Company
	Previous Guidance	Current Guidance

Reported Revenue	4 - 7%	5 - 8%
53rd week impact	(~2%)	(~2%)
Currency impact	0 - 1%	0 - 1%
Organic Revenue(1)	3 - 6%	4 - 7%
Adjusted operating margin	50 – 100 bps expansion YoY	50 – 100 bps expansion YoY
Adjusted earnings per diluted share	Comparable to reported revenue growth	Comparable to reported revenue growth
Free cash flow conversion(2)	~80%	~80%


			First Quarter Fiscal 2027
			Organic
Apheresis			6.0%
MedSurg			5.9%
Total net revenue			5.9%